Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

17.36 +0.11 (+0.64%)
Streaming Delayed Price Updated: 11:46 AM EDT, Sep 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser
From Bausch + Lomb Corporation
Via Business Wire
News headline image
1 Cash-Producing Stock with Exciting Potential and 2 We Ignore
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
News headline image
Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds
From Bausch + Lomb Corporation
Via Business Wire
News headline image
1 Unpopular Stock That Deserves a Second Chance and 2 We Turn Down
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea... 
Via StockStory
News headline image
3 Healthcare Stocks We Steer Clear Of
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry... 
Via StockStory
News headline image
Bausch + Lomb Advances Two Eye Therapies With Blockbuster Sales Potential ↗
Bausch + Lomb (NYSE: BLCO) advances two first-in-class eye drugs to advanced clinical testing, eyeing $2B+ in peak sales. 
Via Benzinga
News headline image
A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q2 Earnings: Bausch + Lomb (NYSE:BLCO) Vs The Rest Of The Pack
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - specialty... 
Via StockStory
News headline image
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal ↗
Bausch + Lomb (NYSE:BLCO) said it plans to advance a dual-action dry eye treatment into Phase III development after a Phase II study showed statistically significant improvement in corneal staining at... 
Via MarketBeat
News headline image
Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
From Bausch + Lomb Corporation
Via Business Wire
News headline image
3 Stocks Under $50 We’re Skeptical Of
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However... 
Via StockStory
News headline image
Insider Sheds Nearly 53,000 Shares of Consumer Health Stock, Valued at Almost $900,000 ↗
Liquidation represents 54% of insider's direct equity stake, executed at $16.78 per share following a 23% stock gain over 12 months. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bausch + Lomb (BLCO) Q2 2026 Earnings Call Transcript ↗
Revenue grew 8% while EBITDA surged 28%, driven by dry eye and surgical strength. 
Via The Motley Fool
Topics Earnings
News headline image
Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb Q2 Earnings Call Highlights ↗
Bausch + Lomb (NYSE:BLCO) reported second-quarter 2026 revenue growth across its vision care, surgical and pharmaceutical businesses, while raising its full-year revenue and adjusted EBITDA outlook.... 
Via MarketBeat
Topics Earnings
News headline image
Bausch + Lomb (NYSE:BLCO) Exceeds Q2 CY2026 Expectations
Eyecare company Bausch + Lomb (NYSE:BLCO) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 9.1% year on year to $1.39 bil... 
Via StockStory
News headline image
Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect
Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings this Wednesday before market hours. Here’s what to expect. Bausch + Lomb beat analysts’ ... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Reasons to Avoid BLCO and 1 Stock to Buy Instead
Over the past six months, Bausch + Lomb’s stock price fell to $15.99. Shareholders have lost 7% of their capital, which is disappointing considering the S&P ... 
Via StockStory
Topics Stocks
News headline image
Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today
What Happened? Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 3.8% in the afternoon session after the company announced its experimental glaucoma t... 
Via StockStory
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate
From Bausch + Lomb
Via Business Wire
News headline image
Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care
From Bausch + Lomb
Via Business Wire
News headline image
Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29
From Bausch + Lomb Corporation
Via Business Wire
News headline image
1 Unpopular Stock That Deserves a Second Chance and 2 We Brush Off
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
Via StockStory
News headline image
New Bausch + Lomb Data Show that Addressing Dry Eye Symptoms is Associated with Improved Quality of Life, Including Lower Anxiety and Increased Self-Confidence
From Bausch + Lomb Corporation
Via Business Wire
News headline image
3 Small-Cap Stocks We Steer Clear Of
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
News headline image
1 Stock Under $50 to Own for Decades and 2 We Turn Down
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline... 
Via StockStory
News headline image
Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States
From Bausch + Lomb Corporation
Via Business Wire
News headline image
Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.